|1.||Chen, W Y: 3 articles (04/2002 - 12/2000)|
|2.||Chen, Wen Y: 2 articles (02/2004 - 08/2002)|
|3.||Peirce, Susan K: 2 articles (02/2004 - 08/2002)|
|4.||Chen, N Y: 2 articles (04/2002 - 12/2000)|
|5.||Li, W: 2 articles (04/2002 - 12/2000)|
|6.||Wagner, T E: 2 articles (01/2001 - 12/2000)|
|7.||Ramamoorthy, P: 2 articles (01/2001 - 12/2000)|
|8.||Beck, Michael T: 1 article (08/2002)|
|9.||Peirce, S K: 1 article (04/2002)|
|10.||Beck, M T: 1 article (04/2002)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2001 - "In this study three independent yet related experiments were carried out regarding the effects of hPRL-G129R in breast cancer cells. "
12/01/2000 - "In the present study, we test the hypothesis that the inhibitory effect of hPRL-G129R in breast cancer cells occurs, at least in part, through the inhibition of oncogene STAT3 activation. "
04/01/2002 - "Based on these results, we believe that hPRL-G129R can be used to improve the outcome of human breast cancer treatment in the near future."
01/01/2001 - "We investigated the possible mechanism(s) of hPRL-G129R induced apoptosis in breast cancer cells. "
11/01/1999 - "We further investigated the mechanism of the inhibitory effects of hPRL-G129R in four hPRLR positive breast cancer cell lines. "
04/01/2002 - "At the end of the 7-week study, it was found that hPRL significantly stimulated the in vivo growth of T-47D xenografts (mean tumor volume, 202 +/- 62 mm(3) as compared to 124 +/- 31 mm(3) in control mice), whereas hPRL-G129R inhibited the tumor growth (mean tumor volume, 79+/-32 mm3). "
04/01/2002 - "In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R."
04/01/2002 - "In this study, we report the in vivo anti-tumor effects of hPRL-G129R in nude mice bearing human breast cancer xenografts (T-47D and MCF-7). "
|2.||Caspase 3 (Caspase-3)
|3.||Estrogen Receptor Modulators (Antiestrogen)
|4.||Messenger RNA (mRNA)
|5.||Prolactin Receptors (Prolactin Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)